To include your compound in the COVID-19 Resource Center, submit it here.
Corbus completed enrollment of about 44 patients in a double-blind, placebo-controlled, U.S. Phase II trial
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury